Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Abstract
Authors
H. Vioix L.A. Eddowes M. Griffiths Z. Gabriel